BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Siwak DR, Carey M, Hennessy BT, Nguyen CT, McGahren Murray MJ, Nolden L, Mills GB. Targeting the epidermal growth factor receptor in epithelial ovarian cancer: current knowledge and future challenges. J Oncol 2010;2010:568938. [PMID: 20037743 DOI: 10.1155/2010/568938] [Cited by in Crossref: 62] [Cited by in F6Publishing: 73] [Article Influence: 4.8] [Reference Citation Analysis]
Number Citing Articles
1 Xiao K, Zheng Q, Bao L. Fentanyl activates ovarian cancer and alleviates chemotherapy-induced toxicity via opioid receptor-dependent activation of EGFR. BMC Anesthesiol 2022;22:268. [PMID: 35999506 DOI: 10.1186/s12871-022-01812-4] [Reference Citation Analysis]
2 Ghose A, Gullapalli SVN, Chohan N, Bolina A, Moschetta M, Rassy E, Boussios S. Applications of Proteomics in Ovarian Cancer: Dawn of a New Era. Proteomes 2022;10:16. [DOI: 10.3390/proteomes10020016] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
3 Nikas IP, Lee C, Song MJ, Kim B, Ryu HS. Biomarkers expression among paired serous ovarian cancer primary lesions and their peritoneal cavity metastases in treatment-naïve patients: A single-center study. Cancer Med 2022. [PMID: 35212471 DOI: 10.1002/cam4.4600] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Lai ZY, Tsai KY, Chang SJ, Chuang YJ. Gain-of-Function Mutant TP53 R248Q Overexpressed in Epithelial Ovarian Carcinoma Alters AKT-Dependent Regulation of Intercellular Trafficking in Responses to EGFR/MDM2 Inhibitor. Int J Mol Sci 2021;22:8784. [PMID: 34445495 DOI: 10.3390/ijms22168784] [Reference Citation Analysis]
5 Yadav V, Deshmukh AV, Kumar V, Gangane NM. Expression of HER2/neu Receptor in Epithelial Ovarian Cancers: An Immunohistochemical Pilot Study in Central India. Indian J Gynecol Oncolog 2021;19. [DOI: 10.1007/s40944-021-00569-x] [Reference Citation Analysis]
6 Mak VC, Li X, Rao L, Zhou Y, Tsao SW, Cheung LW. p85β alters response to EGFR inhibitor in ovarian cancer through p38 MAPK-mediated regulation of DNA repair. Neoplasia 2021;23:718-30. [PMID: 34144267 DOI: 10.1016/j.neo.2021.05.009] [Reference Citation Analysis]
7 Wu F, Yang J, Liu J, Wang Y, Mu J, Zeng Q, Deng S, Zhou H. Signaling pathways in cancer-associated fibroblasts and targeted therapy for cancer. Signal Transduct Target Ther 2021;6:218. [PMID: 34108441 DOI: 10.1038/s41392-021-00641-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
8 Ma Q, Song J, Wang S, He N. MUC1 regulates AKT signaling pathway by upregulating EGFR expression in ovarian cancer cells. Pathol Res Pract 2021;224:153509. [PMID: 34118726 DOI: 10.1016/j.prp.2021.153509] [Reference Citation Analysis]
9 Bolitho C, Moscova M, Baxter RC, Marsh DJ. Amphiregulin increases migration and proliferation of epithelial ovarian cancer cells by inducing its own expression via PI3-kinase signaling. Mol Cell Endocrinol 2021;533:111338. [PMID: 34062166 DOI: 10.1016/j.mce.2021.111338] [Reference Citation Analysis]
10 Sabbah M, Najem A, Krayem M, Awada A, Journe F, Ghanem GE. RTK Inhibitors in Melanoma: From Bench to Bedside. Cancers (Basel) 2021;13:1685. [PMID: 33918490 DOI: 10.3390/cancers13071685] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
11 Alizadeh E, Behlol Ayaz Ahmed K, Raja Solomon V, Gaja V, Bernhard W, Makhlouf A, Gonzalez C, Barreto K, Casaco A, Geyer CR, Fonge H. 89Zr-Labeled Domain II-Specific scFv-Fc ImmunoPET Probe for Imaging Epidermal Growth Factor Receptor In Vivo. Cancers (Basel) 2021;13:560. [PMID: 33535661 DOI: 10.3390/cancers13030560] [Reference Citation Analysis]
12 Yang S, Xia J, Yang Z, Xu M, Li S. Lung cancer molecular mutations and abnormal glycosylation as biomarkers for early diagnosis. Cancer Treatment and Research Communications 2021;27:100311. [DOI: 10.1016/j.ctarc.2021.100311] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
13 Chuang TC, Wu K, Lin YY, Kuo HP, Kao MC, Wang V, Hsu SC, Lee SL. Dual down-regulation of EGFR and ErbB2 by berberine contributes to suppression of migration and invasion of human ovarian cancer cells. Environ Toxicol 2021;36:737-47. [PMID: 33325633 DOI: 10.1002/tox.23076] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
14 Lim WC, Choi HK, Kim KT, Lim TG. Rose (Rosa gallica) Petal Extract Suppress Proliferation, Migration, and Invasion of Human Lung Adenocarcinoma A549 Cells through via the EGFR Signaling Pathway. Molecules 2020;25:E5119. [PMID: 33158043 DOI: 10.3390/molecules25215119] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
15 Parashar D, Nair B, Geethadevi A, George J, Nair A, Tsaih SW, Kadamberi IP, Gopinadhan Nair GK, Lu Y, Ramchandran R, Uyar DS, Rader JS, Ram PT, Mills GB, Pradeep S, Chaluvally-Raghavan P. Peritoneal Spread of Ovarian Cancer Harbors Therapeutic Vulnerabilities Regulated by FOXM1 and EGFR/ERBB2 Signaling. Cancer Res 2020;80:5554-68. [PMID: 33087324 DOI: 10.1158/0008-5472.CAN-19-3717] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
16 Zhang T, Zhang L, Li F. Integrative network analysis identifies potential targets and drugs for ovarian cancer. BMC Med Genomics 2020;13:132. [PMID: 32958005 DOI: 10.1186/s12920-020-00773-2] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
17 Hasan S. An Overview of Promising Biomarkers in Cancer Screening and Detection. Curr Cancer Drug Targets 2020;20:831-52. [PMID: 32838718 DOI: 10.2174/1568009620666200824102418] [Reference Citation Analysis]
18 Begum AA, Toth I, Hussein WM, Moyle PM. Advances in Targeted Gene Delivery. Curr Drug Deliv 2019;16:588-608. [PMID: 31142250 DOI: 10.2174/1567201816666190529072914] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
19 Seraj S, Cho YJ, Lee J, Ahn HJ. Cytoplasmic expression of EGFR shRNA using a modified T7 autogene-based hybrid mRNA/DNA system induces long-term EGFR silencing and prolongs antitumor effects. Biochemical Pharmacology 2020;171:113735. [DOI: 10.1016/j.bcp.2019.113735] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
20 Grapa CM, Mocan T, Gonciar D, Zdrehus C, Mosteanu O, Pop T, Mocan L. Epidermal Growth Factor Receptor and Its Role in Pancreatic Cancer Treatment Mediated by Nanoparticles. Int J Nanomedicine. 2019;14:9693-9706. [PMID: 31849462 DOI: 10.2147/ijn.s226628] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
21 Figueroa V, Rodríguez MS, Lanari C, Lamb CA. Nuclear action of FGF members in endocrine-related tissues and cancer: Interplay with steroid receptor pathways. Steroids 2019;152:108492. [DOI: 10.1016/j.steroids.2019.108492] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
22 Morales-Cruz M, Delgado Y, Castillo B, Figueroa CM, Molina AM, Torres A, Milián M, Griebenow K. Smart Targeting To Improve Cancer Therapeutics. Drug Des Devel Ther 2019;13:3753-72. [PMID: 31802849 DOI: 10.2147/DDDT.S219489] [Cited by in Crossref: 28] [Cited by in F6Publishing: 14] [Article Influence: 9.3] [Reference Citation Analysis]
23 Blucher AS, McWeeney SK, Stein L, Wu G. Visualization of drug target interactions in the contexts of pathways and networks with ReactomeFIViz. F1000Res 2019;8:908. [PMID: 31372215 DOI: 10.12688/f1000research.19592.1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
24 Lee S, Ahn HJ. Anti-EpCAM-conjugated adeno-associated virus serotype 2 for systemic delivery of EGFR shRNA: Its retargeting and antitumor effects on OVCAR3 ovarian cancer in vivo. Acta Biomater 2019;91:258-69. [PMID: 31026519 DOI: 10.1016/j.actbio.2019.04.044] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
25 Tata P, Gondaliya P, Sunkaria A, Srivastava A, Kalia K. Modulation of CD44, EGFR and RAC Pathway Genes (WAVE Complex) in Epithelial Cancers. Curr Pharm Des 2019;25:833-48. [PMID: 30799784 DOI: 10.2174/1381612825666190222143044] [Reference Citation Analysis]
26 Showalter LE, Oechsle C, Ghimirey N, Steele C, Czerniecki BJ, Koski GK. Th1 cytokines sensitize HER-expressing breast cancer cells to lapatinib. PLoS One 2019;14:e0210209. [PMID: 30657766 DOI: 10.1371/journal.pone.0210209] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
27 Wahba J, Natoli M, Whilding LM, Parente-Pereira AC, Jung Y, Zona S, Lam EW, Smith JR, Maher J, Ghaem-Maghami S. Chemotherapy-induced apoptosis, autophagy and cell cycle arrest are key drivers of synergy in chemo-immunotherapy of epithelial ovarian cancer. Cancer Immunol Immunother 2018;67:1753-65. [PMID: 30167862 DOI: 10.1007/s00262-018-2199-8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
28 Lin TC, Chen ST, Huang MC, Huang J, Hsu CL, Juan HF, Lin HH, Chen CH. GALNT6 expression enhances aggressive phenotypes of ovarian cancer cells by regulating EGFR activity. Oncotarget 2017;8:42588-601. [PMID: 28388560 DOI: 10.18632/oncotarget.16585] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
29 Cîrstea AE, Stepan AE, Zăvoi RE, Simionescu CE. EGFR Immunoexpression in Malignant Serous and Mucinous Ovarian Tumors. Curr Health Sci J 2018;44:129-34. [PMID: 30746159 DOI: 10.12865/CHSJ.44.02.06] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
30 Wen KC, Sung PL, Hsieh SL, Chou YT, Lee OK, Wu CW, Wang PH. α2,3-sialyltransferase type I regulates migration and peritoneal dissemination of ovarian cancer cells. Oncotarget 2017;8:29013-27. [PMID: 28423672 DOI: 10.18632/oncotarget.15994] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 8.3] [Reference Citation Analysis]
31 Pang J, Jiang P, Wang Y, Jiang L, Qian H, Tao Y, Shi R, Gao J, Chen Y, Wu Y. Cross-linked hyaluronan gel inhibits the growth and metastasis of ovarian carcinoma. J Ovarian Res 2018;11:22. [PMID: 29510732 DOI: 10.1186/s13048-018-0394-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
32 Cheng JC, Chang HM, Xiong S, So WK, Leung PC. Sprouty2 inhibits amphiregulin-induced down-regulation of E-cadherin and cell invasion in human ovarian cancer cells. Oncotarget 2016;7:81645-60. [PMID: 27835572 DOI: 10.18632/oncotarget.13162] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
33 Brasseur K, Gévry N, Asselin E. Chemoresistance and targeted therapies in ovarian and endometrial cancers. Oncotarget 2017;8:4008-42. [PMID: 28008141 DOI: 10.18632/oncotarget.14021] [Cited by in Crossref: 78] [Cited by in F6Publishing: 75] [Article Influence: 19.5] [Reference Citation Analysis]
34 Rahmanian N, Hosseinimehr SJ, Khalaj A, Noaparast Z, Abedi SM, Sabzevari O. 99mTc labeled HYNIC-EDDA/tricine-GE11 peptide as a successful tumor targeting agent. Med Chem Res 2018;27:890-902. [DOI: 10.1007/s00044-017-2111-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
35 Mehner C, Oberg AL, Goergen KM, Kalli KR, Maurer MJ, Nassar A, Goode EL, Keeney GL, Jatoi A, Radisky DC, Radisky ES. EGFR as a prognostic biomarker and therapeutic target in ovarian cancer: evaluation of patient cohort and literature review. Genes Cancer 2017;8:589-99. [PMID: 28740577 DOI: 10.18632/genesandcancer.142] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 3.4] [Reference Citation Analysis]
36 Momeny M, Zarrinrad G, Moghaddaskho F, Poursheikhani A, Sankanian G, Zaghal A, Mirshahvaladi S, Esmaeili F, Eyvani H, Barghi F, Sabourinejad Z, Alishahi Z, Yousefi H, Ghasemi R, Dardaei L, Bashash D, Chahardouli B, Dehpour AR, Tavakkoly-Bazzaz J, Alimoghaddam K, Ghavamzadeh A, Ghaffari SH. Dacomitinib, a pan-inhibitor of ErbB receptors, suppresses growth and invasive capacity of chemoresistant ovarian carcinoma cells. Sci Rep 2017;7:4204. [PMID: 28646172 DOI: 10.1038/s41598-017-04147-0] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 3.2] [Reference Citation Analysis]
37 Zheng J, Zhao L, Wang Y, Zhao S, Cui M. Clinicopathology of EpCAM and EGFR in Human Epithelial Ovarian Carcinoma. Open Med (Wars) 2017;12:39-44. [PMID: 28401199 DOI: 10.1515/med-2017-0007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
38 Showeil R, Romano C, Valganon M, Lambros M, Trivedi P, Van Noorden S, Sriraksa R, El-Kaffash D, El-Etreby N, Natrajan R, Foroni L, Osborne R, El-Bahrawy M. The status of epidermal growth factor receptor in borderline ovarian tumours. Oncotarget 2016;7:10568-77. [PMID: 26870997 DOI: 10.18632/oncotarget.7257] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
39 Ignacio RM, Kabir SM, Lee ES, Adunyah SE, Son DS. NF-κB-Mediated CCL20 Reigns Dominantly in CXCR2-Driven Ovarian Cancer Progression. PLoS One 2016;11:e0164189. [PMID: 27723802 DOI: 10.1371/journal.pone.0164189] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
40 Mehner C, Oberg AL, Kalli KR, Nassar A, Hockla A, Pendlebury D, Cichon MA, Goergen KM, Maurer MJ, Goode EL, Keeney GL, Jatoi A, Sahin-Tóth M, Copland JA, Radisky DC, Radisky ES. Serine protease inhibitor Kazal type 1 (SPINK1) drives proliferation and anoikis resistance in a subset of ovarian cancers. Oncotarget 2015;6:35737-54. [PMID: 26437224 DOI: 10.18632/oncotarget.5927] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
41 Huang WL, Li Z, Lin TY, Wang SW, Wu FJ, Luo CW. Thyrostimulin-TSHR signaling promotes the proliferation of NIH:OVCAR-3 ovarian cancer cells via trans-regulation of the EGFR pathway. Sci Rep 2016;6:27471. [PMID: 27273257 DOI: 10.1038/srep27471] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
42 Mclachlan J, Lima JPDSN, Dumas L, Banerjee S. Targeted agents and combinations in ovarian cancer: where are we now? Expert Review of Anticancer Therapy 2016;16:441-54. [DOI: 10.1586/14737140.2016.1162101] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
43 Wang K, Li D, Sun L. High levels of EGFR expression in tumor stroma are associated with aggressive clinical features in epithelial ovarian cancer. Onco Targets Ther 2016;9:377-86. [PMID: 26855586 DOI: 10.2147/OTT.S96309] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 2.7] [Reference Citation Analysis]
44 Winner KK, Steinkamp MP, Lee RJ, Swat M, Muller CY, Moses ME, Jiang Y, Wilson BS. Spatial Modeling of Drug Delivery Routes for Treatment of Disseminated Ovarian Cancer. Cancer Res 2016;76:1320-34. [PMID: 26719526 DOI: 10.1158/0008-5472.CAN-15-1620] [Cited by in Crossref: 28] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
45 Nagaraj AB, Joseph P, DiFeo A. miRNAs as prognostic and therapeutic tools in epithelial ovarian cancer. Biomark Med. 2015;9:241-257. [PMID: 25731210 DOI: 10.2217/bmm.14.108] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.9] [Reference Citation Analysis]
46 Momeny M, Ghasemi R, Valenti G, Miranda M, Zekri A, Zarrinrad G, Javadikooshesh S, Yaghmaie M, Alimoghaddam K, Ghavamzadeh A, Ghaffari SH. Effects of silibinin on growth and invasive properties of human ovarian carcinoma cells through suppression of heregulin/HER3 pathway. Tumor Biol 2016;37:3913-23. [DOI: 10.1007/s13277-015-4220-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
47 Granados ML, Hudson LG, Samudio-Ruiz SL. Contributions of the Epidermal Growth Factor Receptor to Acquisition of Platinum Resistance in Ovarian Cancer Cells. PLoS One 2015;10:e0136893. [PMID: 26351843 DOI: 10.1371/journal.pone.0136893] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.9] [Reference Citation Analysis]
48 Sundby E, Han J, Kaspersen SJ, Hoff BH. In vitro baselining of new pyrrolopyrimidine EGFR-TK inhibitors with Erlotinib. Eur J Pharm Sci 2015;80:56-65. [PMID: 26296860 DOI: 10.1016/j.ejps.2015.08.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
49 Wen W, Wu J, Liu L, Tian Y, Buettner R, Hsieh MY, Horne D, Dellinger TH, Han ES, Jove R, Yim JH. Synergistic anti-tumor effect of combined inhibition of EGFR and JAK/STAT3 pathways in human ovarian cancer. Mol Cancer 2015;14:100. [PMID: 25928246 DOI: 10.1186/s12943-015-0366-5] [Cited by in Crossref: 52] [Cited by in F6Publishing: 50] [Article Influence: 7.4] [Reference Citation Analysis]
50 Carvalho S, Lindzen M, Lauriola M, Shirazi N, Sinha S, Abdul-hai A, Levanon K, Korach J, Barshack I, Cohen Y, Onn A, Mills G, Yarden Y. An antibody to amphiregulin, an abundant growth factor in patients’ fluids, inhibits ovarian tumors. Oncogene 2016;35:438-47. [DOI: 10.1038/onc.2015.93] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 3.6] [Reference Citation Analysis]
51 Khabele D, Kabir SM, Dong Y, Lee E, Rice VM, Son DS. Preferential effect of akt2-dependent signaling on the cellular viability of ovarian cancer cells in response to EGF. J Cancer 2014;5:670-8. [PMID: 25258648 DOI: 10.7150/jca.9688] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
52 Paul BT, Blanchard Z, Ridgway M, ElShamy WM. BRCA1-IRIS inactivation sensitizes ovarian tumors to cisplatin. Oncogene 2015;34:3036-52. [PMID: 25132263 DOI: 10.1038/onc.2014.237] [Cited by in Crossref: 19] [Cited by in F6Publishing: 23] [Article Influence: 2.4] [Reference Citation Analysis]
53 Lopez J, Banerjee S, Kaye SB. New developments in the treatment of ovarian cancer--future perspectives. Ann Oncol 2013;24 Suppl 10:x69-76. [PMID: 24265409 DOI: 10.1093/annonc/mdt475] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 3.4] [Reference Citation Analysis]
54 Cho M, Kabir SM, Dong Y, Lee E, Rice VM, Khabele D, Son DS. Aspirin Blocks EGF-stimulated Cell Viability in a COX-1 Dependent Manner in Ovarian Cancer Cells. J Cancer 2013;4:671-8. [PMID: 24155779 DOI: 10.7150/jca.7118] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
55 Liu H, Xiao F, Serebriiskii IG, O'Brien SW, Maglaty MA, Astsaturov I, Litwin S, Martin LP, Proia DA, Golemis EA, Connolly DC. Network analysis identifies an HSP90-central hub susceptible in ovarian cancer. Clin Cancer Res 2013;19:5053-67. [PMID: 23900136 DOI: 10.1158/1078-0432.CCR-13-1115] [Cited by in Crossref: 37] [Cited by in F6Publishing: 25] [Article Influence: 4.1] [Reference Citation Analysis]
56 Parente-Pereira AC, Whilding LM, Brewig N, van der Stegen SJ, Davies DM, Wilkie S, van Schalkwyk MC, Ghaem-Maghami S, Maher J. Synergistic Chemoimmunotherapy of Epithelial Ovarian Cancer Using ErbB-Retargeted T Cells Combined with Carboplatin. J Immunol. 2013;191:2437-2445. [PMID: 23898037 DOI: 10.4049/jimmunol.1301119] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 3.6] [Reference Citation Analysis]
57 Panupinthu N, Yu S, Zhang D, Zhang F, Gagea M, Lu Y, Grandis JR, Dunn SE, Lee HY, Mills GB. Self-reinforcing loop of amphiregulin and Y-box binding protein-1 contributes to poor outcomes in ovarian cancer. Oncogene 2014;33:2846-56. [PMID: 23851501 DOI: 10.1038/onc.2013.259] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 3.4] [Reference Citation Analysis]
58 Nguyen L, Cardenas-Goicoechea SJ, Gordon P, Curtin C, Momeni M, Chuang L, Fishman D. Biomarkers for early detection of ovarian cancer. Womens Health (Lond). 2013;9:171-185; quiz 186-187. [PMID: 23477323 DOI: 10.2217/whe.13.2] [Cited by in Crossref: 31] [Cited by in F6Publishing: 24] [Article Influence: 3.4] [Reference Citation Analysis]
59 Son DS, Kabir SM, Dong Y, Lee E, Adunyah SE. Characteristics of chemokine signatures elicited by EGF and TNF in ovarian cancer cells. J Inflamm (Lond) 2013;10:25. [PMID: 23800251 DOI: 10.1186/1476-9255-10-25] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.2] [Reference Citation Analysis]
60 Kumtepe Y, Halici Z, Sengul O, Kunak CS, Bayir Y, Kilic N, Cadirci E, Pulur A, Bayraktutan Z. High serum HTATIP2/TIP30 level in serous ovarian cancer as prognostic or diagnostic marker. Eur J Med Res 2013;18:18. [PMID: 23800048 DOI: 10.1186/2047-783X-18-18] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
61 Zhu L, Zhao L, Wu M, Chen Z, Li H. B-cell epitope peptide vaccination targeting dimer interface of epidermal growth factor receptor (EGFR). Immunology Letters 2013;153:33-40. [DOI: 10.1016/j.imlet.2013.07.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
62 Cheng JC, Qiu X, Chang HM, Leung PC. HER2 mediates epidermal growth factor-induced down-regulation of E-cadherin in human ovarian cancer cells. Biochem Biophys Res Commun 2013;434:81-6. [PMID: 23542467 DOI: 10.1016/j.bbrc.2013.03.062] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
63 Yeh YM, Chuang CM, Chao KC, Wang LH. MicroRNA-138 suppresses ovarian cancer cell invasion and metastasis by targeting SOX4 and HIF-1α. Int J Cancer 2013;133:867-78. [PMID: 23389731 DOI: 10.1002/ijc.28086] [Cited by in Crossref: 165] [Cited by in F6Publishing: 157] [Article Influence: 18.3] [Reference Citation Analysis]
64 Elit L, Hirte H. Palliative systemic therapy for women with recurrent epithelial ovarian cancer: current options. Onco Targets Ther 2013;6:107-18. [PMID: 23459506 DOI: 10.2147/OTT.S30238] [Cited by in Crossref: 18] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
65 Leone Roberti Maggiore U, Bellati F, Ruscito I, Gasparri ML, Alessandri F, Venturini PL, Ferrero S. Monoclonal antibodies therapies for ovarian cancer. Expert Opin Biol Ther 2013;13:739-64. [PMID: 23373587 DOI: 10.1517/14712598.2013.767328] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
66 Kodigepalli KM, Dutta PS, Bauckman KA, Nanjundan M. SnoN/SkiL expression is modulated via arsenic trioxide-induced activation of the PI3K/AKT pathway in ovarian cancer cells. FEBS Lett. 2013;587:5-16. [PMID: 23178716 DOI: 10.1016/j.febslet.2012.11.003] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
67 Marzinke MA, Choi CH, Chen L, Shih IeM, Chan DW, Zhang H. Proteomic analysis of temporally stimulated ovarian cancer cells for biomarker discovery. Mol Cell Proteomics. 2013;12:356-368. [PMID: 23172893 DOI: 10.1074/mcp.M112.019521] [Cited by in Crossref: 15] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
68 Zand B, Coleman RL, Sood AK. Targeting angiogenesis in gynecologic cancers. Hematol Oncol Clin North Am 2012;26:543-63, viii. [PMID: 22520979 DOI: 10.1016/j.hoc.2012.01.009] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
69 Wilken JA, Badri T, Cross S, Raji R, Santin AD, Schwartz P, Branscum AJ, Baron AT, Sakhitab AI, Maihle NJ. EGFR/HER-targeted therapeutics in ovarian cancer. Future Med Chem 2012;4:447-69. [PMID: 22416774 DOI: 10.4155/fmc.12.11] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 3.1] [Reference Citation Analysis]
70 Hiss D. Optimizing molecular-targeted therapies in ovarian cancer: the renewed surge of interest in ovarian cancer biomarkers and cell signaling pathways. J Oncol 2012;2012:737981. [PMID: 22481932 DOI: 10.1155/2012/737981] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 2.9] [Reference Citation Analysis]
71 Seshacharyulu P, Ponnusamy MP, Haridas D, Jain M, Ganti AK, Batra SK. Targeting the EGFR signaling pathway in cancer therapy. Expert Opin Ther Targets. 2012;16:15-31. [PMID: 22239438 DOI: 10.1517/14728222.2011.648617] [Cited by in Crossref: 428] [Cited by in F6Publishing: 393] [Article Influence: 42.8] [Reference Citation Analysis]
72 Daneshmanesh AH, Hojjat-Farsangi M, Khan AS, Jeddi-Tehrani M, Akhondi MM, Bayat AA, Ghods R, Mahmoudi AR, Hadavi R, Österborg A, Shokri F, Rabbani H, Mellstedt H. Monoclonal antibodies against ROR1 induce apoptosis of chronic lymphocytic leukemia (CLL) cells. Leukemia 2012;26:1348-55. [PMID: 22289919 DOI: 10.1038/leu.2011.362] [Cited by in Crossref: 61] [Cited by in F6Publishing: 66] [Article Influence: 6.1] [Reference Citation Analysis]
73 Alberti C, Pinciroli P, Valeri B, Ferri R, Ditto A, Umezawa K, Sensi M, Canevari S, Tomassetti A. Ligand-dependent EGFR activation induces the co-expression of IL-6 and PAI-1 via the NFkB pathway in advanced-stage epithelial ovarian cancer. Oncogene 2012;31:4139-49. [DOI: 10.1038/onc.2011.572] [Cited by in Crossref: 69] [Cited by in F6Publishing: 71] [Article Influence: 6.3] [Reference Citation Analysis]
74 Jiao Y, Ou W, Meng F, Zhou H, Wang A. Targeting HSP90 in ovarian cancers with multiple receptor tyrosine kinase coactivation. Mol Cancer 2011;10:125. [PMID: 21962244 DOI: 10.1186/1476-4598-10-125] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 2.9] [Reference Citation Analysis]
75 Barbolina MV, Burkhalter RJ, Stack MS. Diverse mechanisms for activation of Wnt signalling in the ovarian tumour microenvironment. Biochem J 2011;437:1-12. [PMID: 21668411 DOI: 10.1042/BJ20110112] [Cited by in Crossref: 50] [Cited by in F6Publishing: 37] [Article Influence: 4.5] [Reference Citation Analysis]
76 Noske A, Schwabe M, Weichert W, Darb-Esfahani S, Buckendahl AC, Sehouli J, Braicu EI, Budczies J, Dietel M, Denkert C. An intracellular targeted antibody detects EGFR as an independent prognostic factor in ovarian carcinomas. BMC Cancer 2011;11:294. [PMID: 21756326 DOI: 10.1186/1471-2407-11-294] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 2.1] [Reference Citation Analysis]
77 Sheng Q, Liu J. The therapeutic potential of targeting the EGFR family in epithelial ovarian cancer. Br J Cancer 2011;104:1241-5. [PMID: 21364581 DOI: 10.1038/bjc.2011.62] [Cited by in Crossref: 105] [Cited by in F6Publishing: 104] [Article Influence: 9.5] [Reference Citation Analysis]